hC contributed an estimated 10% of subjects towards the Pfizer and Moderna COVID-19 vaccine trials
44 PIs with vaccine experience
Conducted over 400 vaccine trials
Lab capabilities include PBMC and IBC certified
Access to and success with enrolling large numbers of special populations including healthy, diverse, elderly, pediatric, and those with co-morbidities
60% of labs have BioSafety Level 2
Ability to scale quickly to accommodate large volume trials using shared resources and platforms
